No Data
No Data
Late night surge! The renminbi and A50 rose, and China concept stocks rose across the board, while gold and silver soared.
Tonight, the U.S. June CPI data was released, showing that inflation in the United States has cooled across the board.
Bank of America Securities downgrades Beigene (06160.HK) target price to HKD 92.09, rating 'neutral'.
Bank of America Securities research report pointed out that Beigene's (06160.HK) independently developed BTK inhibitors zanubrutinib, orelabrutinib, ibrutinib, and acalabrutinib recorded sales of RMB 60.9 million, 26.8 million, 25.3 million, and 0.3 million yuan respectively in May, accounting for 53.7%, 23.7%, 22.3%, and 0.3% of the overall sales in the mainland market. The bank lowered its 2024 forecast due to the updated sales data and intensified competition in the mainland BTK inhibitor market.
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A
BeiGene Is Maintained at Neutral by B of A Securities
BeiGene Is Maintained at Neutral by B of A
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 5.92% B of A Securities $180 → $152.5 Maintains Neutral 05/09/2024 76.43% TD Cowen $236 → $254